Jasper Therapeutics to Host Investor Conference Call and Webcast on January 31, 2023

Rhea-AI Summary

Jasper Therapeutics will host a corporate update conference call on January 31, 2023, from 8:30 am – 9:30 am Eastern Time. The call will be led by the management team and can be accessed by phone or through a live webcast available on their investor relations website. Jasper is focused on developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) for conditions such as chronic spontaneous urticaria and myelodysplastic syndromes (MDS). To date, the drug has shown safety and efficacy in over 130 participants. A replay of the webcast will be available for 90 days.

REDWOOD CITY, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, announced today that it will host an investor conference call and webcast to provide a corporate update on Tuesday, January 31 from 8:30 am – 9:30 am Eastern Time.

The conference call will be hosted by the Jasper management team and can be accessed by dialing 1-877-407-4018 (toll-free domestic) or 1-201-689-8471 (international) or by clicking on this link and requesting a return call. The live webcast, which will include presentation slides, may be accessed via the investor relations section of the Jasper website at www.jaspertherapeutics.com. A replay of the webcast will be available for 90 days.

About Jasper

Jasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic mast and stem cell diseases such as chronic urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) and as a conditioning agent for stem cell transplants for rare diseases such as sickle cell disease (SCD), Fanconi anemia (FA) and severe combined immunodeficiency (SCID). To date, briquilimab has a demonstrated efficacy and safety profile in over 130 dosed subjects and healthy volunteers, with clinical outcomes as a conditioning agent in SCID, acute myeloid leukemia (AML), MDS, FA, and SCD. In addition, briquilimab is being advanced as a transformational non-genotoxic conditioning agent for gene therapy.

Contacts:

John Mullaly (investors)
LifeSci Advisors
617-429-3548
jmullaly@lifesciadvisors.com

Jeet Mahal (investors)
Jasper Therapeutics
650-549-1403
jmahal@jaspertherapeutics.com

Lauren Barbiero (media)
Real Chemistry
646-564-2156
lbarbiero@realchemistry.com

FAQ

What is the date and time of the Jasper Therapeutics conference call?

The conference call is scheduled for January 31, 2023, from 8:30 am to 9:30 am Eastern Time.

How can I access the Jasper Therapeutics conference call?

You can access the call by dialing 1-877-407-4018 domestically or 1-201-689-8471 internationally, or by using the webcast link on their investor relations page.

What is briquilimab developed by Jasper Therapeutics?

Briquilimab is a monoclonal antibody targeting c-Kit (CD117) for chronic mast and stem cell diseases, including chronic urticaria and myelodysplastic syndromes.

How many subjects have been dosed with briquilimab?

Over 130 subjects and healthy volunteers have been dosed with briquilimab.

Will there be a replay of the Jasper Therapeutics conference call?

Yes, a replay of the conference call will be available for 90 days.